• Healthy female or male subjects who, at the time of screening, are between the ages of 18 and 65 years, inclusive.

• Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.

• Body mass index of 18.0 to 32.0 kg/m\^2, inclusive; and a total body weight \> 50 kg up to a maximum of 110 kg.

• Study subjects must have received a quadrivalent meningococcal conjugate vaccine (meningococcal serogroups A, C, W, and Y) within the past 5 years or vaccination a minimum of 14 days prior to initial study drug administration.

• The subject must be capable of understanding the investigational nature, potential risks and benefits of the study and capable of providing valid informed consent.

• Female or male subjects who, at the time of screening, are at least 18 years of age with a total body weight of ≥ 50 kg.

• Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.

• The subject must be capable of understanding the investigational nature, potential risks and benefits of the study and capable of providing valid informed consent.

• The subject must be willing to return to the study center for study treatment and study-related follow-up procedures as required by the protocol.

• Study subjects must have received a quadrivalent meningococcal conjugate vaccine (meningococcal serogroups A, C, W, and Y) within the past 5 years or vaccination a minimum of 14 days prior to initial study drug administration.

• The Participant Identification Center (PIC) site will have provided evidence that the PIC site used to confirm diagnosis of Cold Agglutinin Disease (CAD)

• Primary Cold Agglutinin Disease (CAD) or CAD secondary to active lymphoid or other hematologic malignancy (Cold Agglutinin Syndrome).

• Hemoglobin level \< 105 gram per liter (g/L).

• Bilirubin level above the normal reference range.